Abstract
The development in the last decade of new agents for the treatment of Metastatic Kidney Cancer has improved the quality of life and the survival of these patients. New target therapies (TKI), Immune-Checkpoint Inhibitors (ICI) and new combinations of these molecules, in addition to synergies, have changed the possibilities of first-line treatments. A better understanding of the biology of each tumor and its microenvironment, will allow us to select patients who benefit from different treatments. Genetic advances and molecular characterization have provided an important prognostic value; nonetheless, we need biomarkers which enable us to individualize treatments and develop new therapeutic lines.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
